Detection of soluble HLA-G molecules in plasma and amniotic fluid

Tissue Antigens. 1999 Jan;53(1):14-22. doi: 10.1034/j.1399-0039.1999.530102.x.

Abstract

Although the cDNA sequence of HLA-G antigens is compatible with their expression as soluble molecules (sHLA-G), the determination of native sHLA-G levels in body fluids has not yet been described. The lack of this information is likely to reflect the difficulties in developing an assay suitable to measure sHLA-G antigens in the presence of soluble HLA-A, -B and -C (sHLA-I) antigens, since most of the available anti-HLA-G mAb do not detect soluble beta2-m associated HLA-G antigens or crossreact with sHLA-I antigens. Therefore, we have developed a two-step assay which eliminates the interference of classical HLA class I antigens. In the first step, the sample is depleted of sHLA-I antigens and of HLA-E antigens with mAb TP25.99. Then, HLA-G antigens are captured with mAb W6/32 and detected with anti-beta2-m mAb in ELISA. Utilizing this assay, sHLA-G antigen levels were measured in EDTA plasma from 92 controls with known HLA types, 28 women at delivery and the corresponding cord bloods and in 50 amniotic fluids. Mean sHLA-G plasma levels did not differ between males (24.9+/-3.0 SEM ng/ml; n=42) and females (20.1+/-2.1 SEM ng/ml; n = 50). However, sHLA-G levels in HLA-A11 positive probands (mean: 13.0+/-4.4 SEM ng/ml; n=12) were significantly (P<0.05) lower than in HLA-A11 negative ones (mean: 24.5+/-2.0 SEM ng/ml; n=80). sHLA-G levels in women at delivery (mean: 22.9+/-2.2 SEM ng/ml; n=28) were in the range of controls but were significantly (P<0.001) reduced in the corresponding cord bloods (mean: 13.8+/-1.5 SEM ng/ml; n=28). sHLA-G levels in amniotic fluids (mean: 15.5 + 1.0 SEM ng/ml; n=50) were significantly (P<0.001) lower than in plasma. sHLA-G levels were 5 and 11% of those of sHLA-I antigens in plasmas and amniotic fluids, respectively. Individual sHLA-G levels were not correlated with sHLA-I levels. SDS-PAGE analysis of plasma sHLA-G antigens revealed two molecular variants with a 35 kD and a 27 kD MW corresponding to the sizes of sHLA-G1 and -G2 isoforms. In conclusion, our study has shown that the two-step assay we have developed is reliable in measuring sHLA-G antigen levels. This assay will facilitate the analysis of the biological and clinical significance of sHLA-G antigens in plasma.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Amniotic Fluid / immunology*
  • Animals
  • Antibodies, Monoclonal / immunology
  • Blood Protein Electrophoresis
  • Cell Line
  • Choriocarcinoma / pathology
  • Cross Reactions
  • Culture Media, Serum-Free
  • Drosophila melanogaster / cytology
  • Electrophoresis, Polyacrylamide Gel
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fetal Blood / immunology*
  • HLA Antigens / analysis*
  • HLA Antigens / blood
  • HLA Antigens / genetics
  • HLA Antigens / immunology
  • HLA-E Antigens
  • HLA-G Antigens
  • Histocompatibility Antigens Class I / analysis*
  • Histocompatibility Antigens Class I / blood
  • Histocompatibility Antigens Class I / genetics
  • Histocompatibility Antigens Class I / immunology
  • Humans
  • Immunomagnetic Separation
  • Infant, Newborn
  • K562 Cells
  • Male
  • Molecular Weight
  • Plasma / immunology*
  • Pregnancy
  • RNA Splicing
  • Sensitivity and Specificity
  • Sex Characteristics
  • Solubility
  • Transfection
  • Tumor Cells, Cultured
  • Uterine Neoplasms / pathology
  • beta 2-Microglobulin / immunology

Substances

  • Antibodies, Monoclonal
  • Culture Media, Serum-Free
  • HLA Antigens
  • HLA-G Antigens
  • Histocompatibility Antigens Class I
  • beta 2-Microglobulin